IBIO Stock UPDATES Ibio Inc (IBIO) 3.21 10/19/2014 09:31:04

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ibio Inc (IBIO) 3.21 $IBIO

How to Trade the Market's Most-Active Stocks
at The Street - Fri Oct 17, 2:18PM CDT
Here's how to trade some of the most active stocks on the market today.
GE: 24.82 (+0.57), HAL: 52.60 (+1.43), IBIO: 3.21 (+1.32)

Why iBio (IBIO) Stock Continues to Soar Today
at The Street - Fri Oct 17, 9:33AM CDT
Shares of iBio (IBIO) surged again in morning trading Friday as the Ebola outbreak continues.
IBIO: 3.21 (+1.32)

Why iBio (IBIO) Stock Is Soaring Today
at The Street - Thu Oct 16, 8:58AM CDT
Shares of iBio (IBIO) soared in morning trading Thursday after the company announced it has offered to aid the U.S. government in fighting Ebola with its proprietary antibody production technology.
IBIO: 3.21 (+1.32)

iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak
Marketwired - Thu Oct 16, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO) today confirmed, in response to shareholder and media inquiries: (i) the applicability of its issued U.S. iBioLaunch(TM) platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus, and (ii) that iBio has an ongoing relationship with Caliber Biotherapeutics LLC reflected by a License and Collaboration Agreement dated February 14, 2013 pursuant to which iBio and Caliber have been collaborating on commercial opportunities for recombinant antibodies and antibody-related proteins based on the speed, efficiency, and cost advantages of producing pharmaceutical proteins in plants instead of with bioreactor-based manufacturing methods.
IBIO: 3.21 (+1.32)

Market Maker Surveillance Report. AHPI, APT, LAKE, IBIO, CDXS, MPO, Losing Stocks With Lowest Price Friction For Tuesday, October 14th 2014
M2 - Wed Oct 15, 3:11AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4904 companies with "abnormal" market making, 2632 companies with positive Friction Factors and 2319 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Allied Healthcare Products Inc (NASDAQ:AHPI), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), Ibio Inc (NYSE:IBIO), Codexis Inc (NASDAQ:CDXS), Midstates Petroleum Company Inc (NYSE:MPO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
APT: 5.55 (-1.28), AHPI: 2.73 (-0.17), MPO: 2.86 (+0.03), CDXS: 2.25 (-0.01), IBIO: 3.21 (+1.32), LAKE: 16.98 (-3.71)

Why Versar (VSR) Stock Is Soaring Today
at The Street - Tue Oct 14, 11:03AM CDT
Versar (VSR) stock is sharply up today as other Ebola-related stocks tumble following a mixed report by the World Health Organization.
APT: 5.55 (-1.28), VSR: 4.50 (-1.17), LAKE: 16.98 (-3.71), IBIO: 3.21 (+1.32)

Why iBio (IBIO) Stock Is Plummeting Today
at The Street - Tue Oct 14, 9:10AM CDT
Shares of iBio (IBIO) plunged Tuesday after the World Health Organization said the number of new Ebola cases in the hardest-hit areas is declining.
IBIO: 3.21 (+1.32)

Market Maker Surveillance Report. S, BTU, IBIO, VALE, SIMH, FB, Bullishly Biased Price Friction For Monday, October 13th 2014
M2 - Tue Oct 14, 4:08AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 4783 companies with "abnormal" market making, 1672 companies with positive Friction Factors and 3138 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Sprint Nextel Corp (NYSE:S), Peabody Energy Corp (NYSE:BTU), Ibio Inc (NYSE:IBIO), Vale SA (NYSE:VALE), SANOMEDICS INTERNATIONAL HOL (OTC:SIMH), Facebook Inc (NASDAQ:FB). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BTU: 11.03 (-0.26), FB: 75.95 (+3.32), VALE: 10.94 (-0.20), S: 6.03 (+0.09), IBIO: 3.21 (+1.32)

Why iBio (IBIO) Stock Hit a One-Year High Today
at The Street - Mon Oct 13, 9:39AM CDT
Shares of iBio (IBIO) were soaring in morning trading Monday after a nurse in Texas was diagnosed with the Ebola virus, which deepened concerns about an outbreak in the U.S.
IBIO: 3.21 (+1.32)

iBio Reports on Filing of 2014 Annual Report
Marketwire - Fri Oct 03, 4:00PM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, announced, as required by Section 610(b) of the NYSE MKT Company Guide, that the Company's Annual Report on Form 10-K was filed with the Securities and Exchange Commission on September 29, 2014, and that its audited consolidated financial statements for the fiscal year ended June 30, 2014 contained therein included a going concern qualification from its independent public accounting firm. This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended June 30, 2014. The Company recommends examination of the Company's complete Annual Report for a better understanding of the Company and its audited consolidated financial statements.
IBIO: 3.21 (+1.32)

ACHN, IBIO, CRAY, IBCA, QLTY, PIY Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Sep 16, 6:08AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Achillion Pharmaceuticals Inc (NASDAQ:ACHN), Ibio Inc (NYSE:IBIO), Cray Inc (NASDAQ:CRAY), Intervest Bancshares Corp (NASDAQ:IBCA), Quality Distribution Inc (NASDAQ:QLTY), Preferredplus Trust Series Czn 1 (NYSE IY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PIY: 25.56 (-0.37), QLTY: 11.74 (+0.54), ACHN: 10.97 (+0.08), IBIO: 3.21 (+1.32), IBCA: 9.60 (-0.02), CRAY: 27.91 (+0.39)

iBio names Dr Thomas A. Medsger Jr to clinical advisory board
M2 - Wed Sep 03, 5:56AM CDT
Biotechnology company iBio (NYSE MKT:IBIO) revealed on Tuesday the addition of Dr Thomas A. Medsger Jr, MD to its clinical advisory board.
IBIO: 3.21 (+1.32)

Dr. Thomas A. Medsger Jr. Joins iBio Clinical Advisory Board
Marketwire - Tue Sep 02, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of biotechnology for developing and manufacturing plant-made pharmaceutical products, has appointed Thomas A. Medsger Jr., M.D., to its clinical advisory board.
IBIO: 3.21 (+1.32)

Yellow Fever - Therapeutics Pipeline Review, H2 2014 - 6 Companies & 5 Drug Profiles
M2 - Mon Sep 01, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x2n27t/yellow_fever) has announced the addition of the "Yellow Fever - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Yellow Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Yellow Fever and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Yellow Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Yellow Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Yellow Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Yellow Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Panacea Biotec Limited - Janssen Pharmaceuticals, Inc. - NewLink Genetics Corporation - iBio, Inc. - Arbovax, Inc. - Themis Bioscience GmbH Drug Profiles - Flaviviruses Infection Vaccine - LCTA-949 - DiTU - BG-323 - yellow fever [YF-17D] (polyvalent) vaccine For more information visit http://www.researchandmarkets.com/research/x2...llow_fever
NLNK: 29.35 (-2.52), IBIO: 3.21 (+1.32)

iBio Receives European Patent Allowances for Protein Expression Technology
Marketwire - Thu Aug 28, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, received notices of intention to grant for two European patent applications claiming novel protein expression technologies.
IBIO: 3.21 (+1.32)

iBio Enters Into $10 Million Common Stock Purchase Agreement With Aspire Capital
Marketwire - Tue Aug 26, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, today announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC. Within two business days of approval of the transaction by the NYSE MKT, Aspire Capital will complete an initial purchase of 1,136,354 shares of common stock at $0.44 per share, the closing sale price of iBio's common stock on the NYSE MKT on the business day prior to entry into the purchase agreement with Aspire Capital, for proceeds of $500,000. After the SEC declares a registration statement effective relating to the transaction, Aspire Capital has committed to purchase up to $9.5 million in additional shares of common stock over a 24 month period. No warrants are associated with this agreement.
IBIO: 3.21 (+1.32)

GBLI, IBIO, HBOS, CASS, CLMS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Aug 18, 7:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Global Indemnity PLC (NASDAQ:GBLI), Ibio Inc (NYSE:IBIO), Heritage Financial Group Inc (NASDAQ:HBOS), CASS INFORMATION SYSTEMS, INC. (NASDAQ:CASS), Calamos Asset Management Inc (NASDAQ:CLMS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLMS: 11.32 (-0.55), CASS: 42.29 (-1.91), IBIO: 3.21 (+1.32), GBLI: 28.01 (-0.71), HBOS: 20.31 (+0.93)

iBio Forms Marketing Collaboration With Kanematsu Chemicals Corporation to Target Japanese Market
Marketwire - Thu Aug 14, 7:32AM CDT
iBio, Inc. (NYSE MKT: IBIO), and Kanematsu Chemicals Corporation, part of Kanematsu Corporation (TSE: 8020), have entered into a collaboration agreement under which Kanematsu Chemicals Corporation will market the novel iBioLaunch(TM) platform in Japan.
IBIO: 3.21 (+1.32)

iBio Appoints Another IPF Expert, Dr. J. Terrill Huggins, to Clinical Advisory Board
Marketwire - Wed Jul 30, 7:31AM CDT
iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has appointed J. Terrill Huggins, M.D. to its clinical advisory board. The board of science and medical experts is assisting iBio in its clinical and product strategy.
IBIO: 3.21 (+1.32)

iBio names Dr Richard M. Silver to clinical advisory board
M2 - Tue Jul 22, 8:30AM CDT
Plant biotechnology company iBio (NYSE MKT:IBIO) revealed on Monday the addition of Dr Richard M. Silver, MD to its clinical advisory board.
IBIO: 3.21 (+1.32)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Choate's Expands to New Mid-South Markets

Updated Category News Views 149

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 119

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 142

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 140

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 219

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 182

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 139

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 102

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Strive Inc's New Chief Investment Officer to Boost Bitcoin Focus

Updated Category News Views 194

Strive Inc Welcomes Ben Werkman as CIO Strive, Inc. (NASDAQ: ASST), a pioneering company in Bitcoin treasury management, has introduced Ben Werkman as its new Chief Investment Officer (CIO). Ben brings with him a wealth of knowledge and experience aimed at enhancing the company's strategy in digital assets and investing, particularly focusing on Bitcoin. Ben Werkman's...

Continue Reading
Experience Latashá's 'muva_nature' at Ace Hotel Palm Springs

Updated Category News Views 265

Latashá's Exhibition 'muva_nature' at Ace Hotel Ace Hotel & Swim Club Palm Springs is proud to host an innovative exhibition titled 'muva_nature', featuring renowned artist Latashá. This exhibition coincides with the vibrant Coachella season, marking a momentous occasion for art enthusiasts and visitors alike. Latashá, celebrated for her music and performance art,...

Continue Reading
Clovity Welcomes Mahesh Shah as Key Operating Advisor for Growth

Updated Category News Views 119

Clovity Announces Mahesh Shah's Appointment Clovity, a prominent Atlassian Platinum Solution Partner renowned for its enterprise-grade service modernization, has recently appointed Mahesh Shah as an Operating Advisor. This move aims to accelerate the company's progress in utilizing AI-powered Atlassian solutions across regulated sectors. An Experienced Leader in...

Continue Reading
Orion Corporation Shifts Focus After Ending ODM-111 Program

Updated Category News Views 139

Orion Corporation Concludes ODM-111 Development Program Orion Corporation has made a crucial decision regarding the future of its ODM-111 project, announcing the termination of the development program. This conclusion stems from a comprehensive evaluation of a recent non-clinical toxicology study, which assessed the risk-benefit ratio of the molecule. The outcomes...

Continue Reading
SEO Contracts: Key to Transforming Law Firm Marketing Strategies

Updated Category News Views 55

Understanding the Importance of SEO Contracts for Law Firms In the competitive world of law firm marketing, a recent study highlights the essential role that well-defined SEO contracts play in ensuring success. Research conducted by experts underscores the critical value of transparency through detailed agreements, reporting, and clear responsibilities, emphasizing that...

Continue Reading